# Onconic Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/onconic-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Seoul, South Korea
- Website: www.onconic.co.kr
- Total disclosed funding: $44M
- Latest round: Series B (Dec 8, 2022)
- Investors on record: 11

## About

Based in Seoul, South Korea, Onconic Therapeutics Inc., a subsidiary of Jeil Pharmaceutical, operates as a drug development company. In March 2021, Onconic Therapeutics Inc. raised KRW 27.5 billion in Series A funding from BNH Investment, DAOL Investment, and Premier Partners. The round gives the company a pre-money valuation of KRW 70 billion. In December 2022, Onconic Therapeutics Inc. raised KRW 26 billion in Series B funding from AJU IB Investment, K2 Investment Partners, KDB Bank, and SL Investment. As of 2022, the company’s CEO is John Kim.

Onconic conducts various research and development activities in order to develop drugs for cancer and gastrointestinal diseases. The product line of the company includes OCN-201, which is an anti-cancer drug, and Zastaprazan (OCN-101), which is a potassium-competitive acid blocker (P-CAB) for gastric acid-related diseases.

The company plans to use the funds raised in December 2022 to wrap up the Phase III clinical trials of drug candidate OCN-101 and the Phase II clinical trials of OCN-201, an anti-cancer drug candidate, and secure approvals for new drug development.

## Funding rounds

- Series B, Dec 8, 2022, $20M — Korea Development Bank, AJU IB Investment, WOORI Venture Partners, SL Investment, Premier Partners, DT&Investment, BNH Investment, K2 Investment Partners, Stonebridge Ventures
- Series A, Mar 22, 2021, $24M — WOORI Venture Partners, Industrial Bank of Korea, Premier Partners, BNH Investment, Stonebridge Ventures, Shinvestor N Partners

## Investors

- WOORI Venture Partners (https://capitalatlas.ai/funds/woori-venture-partners) — Series A, Series B
- Industrial Bank of Korea — Series A
- Premier Partners (https://capitalatlas.ai/funds/premier-partners) — Series A, Series B
- BNH Investment (https://capitalatlas.ai/funds/bnh-investment) — Series A, Series B
- Stonebridge Ventures — Series A, Series B
- Shinvestor N Partners — Series A
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series B
- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series B
- SL Investment (https://capitalatlas.ai/funds/sl-investment) — Series B
- DT&Investment (https://capitalatlas.ai/funds/dt-investment) — Series B
- K2 Investment Partners (https://capitalatlas.ai/funds/k2-investment-partners) — Series B